The pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST-elevation myocardial infarction: The first report from Iranian population

• Main Authors: Naser Aslanabadi (Author), Naser Safaie (Author), Faezeh Shadfar (Author), Mohammad Reza Taban-Sadeghi (Author), Hossein Feizpour (Author), Simin Ozar Mashayekhi (Author), Hadi Hamishehkar (Author), Naser Khezerlou Aghdam (Author), Samaneh Dousti (Author), Hossein Namdar (Author), Taher Entezari-Maleki (Author)
• Formato: Livro
• Publicado em: Wolters Kluwer Medknow Publications, 2015-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Objective: Acute myocardial infarction (AMI) is one of the main leading causes of mortality and morbidity. Reteplase is a fibrin-specific thrombolytic which is used in the treatment of AMI. There is a limited number of studies reporting the postmarketing adverse drug reactions (ADRs) induced by rete...